Compare PPBT & BCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPBT | BCG |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 39.8M |
| IPO Year | 2014 | N/A |
| Metric | PPBT | BCG |
|---|---|---|
| Price | $3.97 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 39.9K | 3.4K |
| Earning Date | 03-13-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $56.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.36 |
| 52 Week High | $5.18 | $3.44 |
| Indicator | PPBT | BCG |
|---|---|---|
| Relative Strength Index (RSI) | 67.36 | 48.61 |
| Support Level | $0.57 | $1.94 |
| Resistance Level | $5.18 | $2.40 |
| Average True Range (ATR) | 0.37 | 0.08 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 20.59 | 69.70 |
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.